Promega said it plans to use the technology to create new research products for investigating endogenous biology.
Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.
Verogen's ForenSeq kit and Thermo Fisher Scientific's Precision ID Whole Genome Panel can now be used to create DNA profiles for a national repository.
The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.
Promega said it will combine the CRISPR technology with its own products that are designed for knock-in of genetic reporters into cells or cell lines.
Of the six kits, the team found that Qiagen and Norgen's spin column tools recovered the highest amount of DNA across a range of base pair lengths.
This week's news includes MolecularMD, Agendia, Promega, and NRGene.
The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
Promega would first seek clearance for an assay that detects dMMR in colorectal cancer patients, and could seek a far broader clearance in the long term.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.